Dovitinib

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Dovitinib in Neuroendocrine Tumors

Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Maintenance Dovitinib for Colorectal and Pancreas Cancer

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands